These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1501 related articles for article (PubMed ID: 28408243)

  • 41. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA.
    Del Re M; Petrini I; Mazzoni F; Valleggi S; Gianfilippo G; Pozzessere D; Chella A; Crucitta S; Rofi E; Restante G; Miccoli M; Garassino MC; Danesi R
    Clin Lung Cancer; 2020 May; 21(3):232-237. PubMed ID: 31735523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
    Jänne PA; Ou SI; Kim DW; Oxnard GR; Martins R; Kris MG; Dunphy F; Nishio M; O'Connell J; Paweletz C; Taylor I; Zhang H; Goldberg Z; Mok T
    Lancet Oncol; 2014 Dec; 15(13):1433-1441. PubMed ID: 25456362
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
    Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
    BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
    Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M
    BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.
    Leighl NB; Rizvi NA; de Lima LG; Arpornwirat W; Rudin CM; Chiappori AA; Ahn MJ; Chow LQ; Bazhenova L; Dechaphunkul A; Sunpaweravong P; Eaton K; Chen J; Medley S; Poondru S; Singh M; Steinberg J; Juergens RA; Gadgeel SM
    Clin Lung Cancer; 2017 Jan; 18(1):34-42.e2. PubMed ID: 27686971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
    Horn L; Gettinger S; Camidge DR; Smit EF; Janjigian YY; Miller VA; Pao W; Freiwald M; Fan J; Wang B; Chand VK; Groen HJM
    Lung Cancer; 2017 Nov; 113():51-58. PubMed ID: 29110849
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
    Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Huang Y; Carbone DP; Gerstner GJ; Lerner RE; Rubin JL; Owonikoko TK; Stella PJ; Steen PD; Khalid AA; Ramalingam SS;
    Lancet Oncol; 2016 Dec; 17(12):1661-1671. PubMed ID: 27825638
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study.
    Shi Y; Hu X; Zhang S; Lv D; Wu L; Yu Q; Zhang Y; Liu L; Wang X; Cheng Y; Ma Z; Niu H; Wang D; Feng J; Huang C; Liu C; Zhao H; Li J; Zhang X; Jiang Y; Gu C
    Lancet Respir Med; 2021 Aug; 9(8):829-839. PubMed ID: 33780662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer.
    Kishi K; Sakai H; Seto T; Kozuki T; Nishio M; Imamura F; Nokihara H; Satouchi M; Nakagawa S; Tahata T; Nakagawa K
    Cancer Treat Res Commun; 2019; 18():100113. PubMed ID: 30472556
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
    Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.
    Reckamp KL; Koczywas M; Cristea MC; Dowell JE; Wang HJ; Gardner BK; Milne GL; Figlin RA; Fishbein MC; Elashoff RM; Dubinett SM
    Cancer; 2015 Sep; 121(18):3298-306. PubMed ID: 26033830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
    Quoix E; Lena H; Losonczy G; Forget F; Chouaid C; Papai Z; Gervais R; Ottensmeier C; Szczesna A; Kazarnowicz A; Beck JT; Westeel V; Felip E; Debieuvre D; Madroszyk A; Adam J; Lacoste G; Tavernaro A; Bastien B; Halluard C; Palanché T; Limacher JM
    Lancet Oncol; 2016 Feb; 17(2):212-223. PubMed ID: 26727163
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
    Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
    Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.
    Brueckl WM; Achenbach HJ; Ficker JH; Schuette W
    BMC Cancer; 2018 Mar; 18(1):333. PubMed ID: 29587656
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial.
    Miyamoto S; Azuma K; Ishii H; Bessho A; Hosokawa S; Fukamatsu N; Kunitoh H; Ishii M; Tanaka H; Aono H; Nakahara Y; Kusaka K; Hosomi Y; Kikuchi N; Mori Y; Itani H; Hamada A; Yamada K; Okamoto H
    JAMA Oncol; 2020 Jul; 6(7):e201250. PubMed ID: 32407455
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
    Goto K; Nishio M; Yamamoto N; Chikamori K; Hida T; Maemondo M; Katakami N; Kozuki T; Yoshioka H; Seto T; Fukuyama T; Tamura T
    Lung Cancer; 2013 Oct; 82(1):109-14. PubMed ID: 23910906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
    Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
    Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
    Tournigand C; Chibaudel B; Samson B; Scheithauer W; Vernerey D; Mésange P; Lledo G; Viret F; Ramée JF; Tubiana-Mathieu N; Dauba J; Dupuis O; Rinaldi Y; Mabro M; Aucoin N; Latreille J; Bonnetain F; Louvet C; Larsen AK; André T; de Gramont A
    Lancet Oncol; 2015 Nov; 16(15):1493-1505. PubMed ID: 26474518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 76.